ub-612
Vaccineexperimental
Clinical trial activity
6 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Sep 25, 2020 (NCT04545749)
Timeline
Indications
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05293665 | Phase 3 | Mar 16, 2022 | Coalition for Epidemic Preparedness Innovations, Syneos Health, Vaxxinity, Inc. |
| NCT05167253 | Phase 1 | Feb 15, 2022 | United Biomedical |
| NCT04967742 | Phase 1 | Aug 5, 2021 | United Biomedical, Vaxxinity, Inc. |
| NCT04683224 | Phase 2/Phase 3 (Phase 3) | Feb 1, 2021 | Diagnósticos da América S/A (DASA), University of California, San Francisco, Vaxxinity, Inc. |
| NCT04773067 | Phase 2 | Jan 30, 2021 | United Biomedical, Vaxxinity, Inc. |
| NCT04545749 | Phase 1 | Sep 25, 2020 | COVAXX, United Biomedical, Vaxxinity, Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vaxxinity, Inc. | For profit | 5 | 2 | 3 | 2020 |
| United Biomedical | For profit | 4 | 4 | 2 | 2020 |
| Coalition for Epidemic Preparedness Innovations | Academic/Hospital | 1 | 0 | 1 | 2022 |
| COVAXX | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Diagnósticos da América S/A (DASA) | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Syneos Health | For profit | 1 | 0 | 1 | 2022 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2021 |
7 organizations
Page 1 / 1